<?xml version='1.0' encoding='utf-8'?>
<document id="18342586"><sentence text="Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study."><entity charOffset="123-134" id="DDI-PubMed.18342586.s1.e0" text="nateglinide" /><entity charOffset="136-146" id="DDI-PubMed.18342586.s1.e1" text="cilostazol" /><entity charOffset="173-195" id="DDI-PubMed.18342586.s1.e2" text="3,4-dehydro-cilostazol" /><pair ddi="false" e1="DDI-PubMed.18342586.s1.e0" e2="DDI-PubMed.18342586.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18342586.s1.e0" e2="DDI-PubMed.18342586.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s1.e0" e2="DDI-PubMed.18342586.s1.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s1.e1" e2="DDI-PubMed.18342586.s1.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s1.e1" e2="DDI-PubMed.18342586.s1.e2" /></sentence><sentence text="Nateglinide (NTG), an insulin secretogogue, has been studied in rats for drug-drug interaction with cilostazol (CLZ), an antiplatelet agent commonly used in diabetics"><entity charOffset="0-11" id="DDI-PubMed.18342586.s2.e0" text="Nateglinide" /><entity charOffset="13-16" id="DDI-PubMed.18342586.s2.e1" text="NTG" /><entity charOffset="100-110" id="DDI-PubMed.18342586.s2.e2" text="cilostazol" /><entity charOffset="112-115" id="DDI-PubMed.18342586.s2.e3" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e0" e2="DDI-PubMed.18342586.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e0" e2="DDI-PubMed.18342586.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e0" e2="DDI-PubMed.18342586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e0" e2="DDI-PubMed.18342586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e1" e2="DDI-PubMed.18342586.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e1" e2="DDI-PubMed.18342586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e1" e2="DDI-PubMed.18342586.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e2" e2="DDI-PubMed.18342586.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s2.e2" e2="DDI-PubMed.18342586.s2.e3" /></sentence><sentence text=" We developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) based method that is capable of simultaneous monitoring plasma levels of nateglinide, cilostazol, and its active metabolite 3,4-dehydro-cilostazol (DCLZ)"><entity charOffset="147-158" id="DDI-PubMed.18342586.s3.e0" text="nateglinide" /><entity charOffset="160-170" id="DDI-PubMed.18342586.s3.e1" text="cilostazol" /><entity charOffset="198-220" id="DDI-PubMed.18342586.s3.e2" text="3,4-dehydro-cilostazol" /><entity charOffset="222-226" id="DDI-PubMed.18342586.s3.e3" text="DCLZ" /><entity charOffset="223-226" id="DDI-PubMed.18342586.s3.e4" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e0" e2="DDI-PubMed.18342586.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e0" e2="DDI-PubMed.18342586.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e0" e2="DDI-PubMed.18342586.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e0" e2="DDI-PubMed.18342586.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e0" e2="DDI-PubMed.18342586.s3.e4" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e1" e2="DDI-PubMed.18342586.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e1" e2="DDI-PubMed.18342586.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e1" e2="DDI-PubMed.18342586.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e1" e2="DDI-PubMed.18342586.s3.e4" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e2" e2="DDI-PubMed.18342586.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e2" e2="DDI-PubMed.18342586.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e2" e2="DDI-PubMed.18342586.s3.e4" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e3" e2="DDI-PubMed.18342586.s3.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s3.e3" e2="DDI-PubMed.18342586.s3.e4" /></sentence><sentence text=" All analytes including the internal standard (Repaglinide) were chromatographed on reverse phase C(18) column (50 mm x 4"><entity charOffset="47-58" id="DDI-PubMed.18342586.s4.e0" text="Repaglinide" /></sentence><sentence text="6mm i" /><sentence text="d" /><sentence text=", 5 microm) using acetonitrile: 2mM ammonium acetate buffer, pH 3"><entity charOffset="18-30" id="DDI-PubMed.18342586.s7.e0" text="acetonitrile" /><entity charOffset="32-52" id="DDI-PubMed.18342586.s7.e1" text="2mM ammonium acetate" /><pair ddi="false" e1="DDI-PubMed.18342586.s7.e0" e2="DDI-PubMed.18342586.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18342586.s7.e0" e2="DDI-PubMed.18342586.s7.e1" /></sentence><sentence text="4 (90:10, v/v) as mobile phase at a flow rate 0" /><sentence text="4 ml/min in an isocratic mode" /><sentence text=" The detection of analyte was performed on LC-MS/MS system in the multiple reaction monitoring (MRM) mode" /><sentence text=" The quantitations for analytes were based on relative concentration" /><sentence text=" The method was validated over the concentration range of 20-2000 ng/ml and the lower limit of quantitation was 20 ng/ml" /><sentence text=" The recoveries from spiked control samples were &gt;79% for all analytes and internal standard" /><sentence text=" Intra- and inter-day accuracy and precision of validated method were with in the acceptable limits of &lt;15% at all concentration" /><sentence text=" The quantitation method was successfully applied for simultaneous estimation of NTG, CLZ and DCLZ in a pharmacokinetic drug-drug interaction study in Wistar rats"><entity charOffset="81-100" id="DDI-PubMed.18342586.s15.e0" text="NTG" /><entity charOffset="86-105" id="DDI-PubMed.18342586.s15.e1" text="CLZ" /><entity charOffset="95-114" id="DDI-PubMed.18342586.s15.e2" text="CLZ" /><entity charOffset="94-113" id="DDI-PubMed.18342586.s15.e3" text="DCLZ" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e0" e2="DDI-PubMed.18342586.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e0" e2="DDI-PubMed.18342586.s15.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e0" e2="DDI-PubMed.18342586.s15.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e0" e2="DDI-PubMed.18342586.s15.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e1" e2="DDI-PubMed.18342586.s15.e1" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e1" e2="DDI-PubMed.18342586.s15.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e1" e2="DDI-PubMed.18342586.s15.e2" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e3" e2="DDI-PubMed.18342586.s15.e3" /><pair ddi="false" e1="DDI-PubMed.18342586.s15.e3" e2="DDI-PubMed.18342586.s15.e2" /></sentence><sentence text="" /></document>